Patent Filed: Peptide Augmentation Technology
- lukemarshall93
- Jun 16
- 3 min read
Updated: Jun 16
Australian Patent Application 2025902422 filed 13 June, 2025
Great news!
Biotome has filed a provisional patent for our novel peptide modification technology that dramatically increases ELISA sensitivity without the complexity and costs of traditional conjugation methods.
This patent will protect the technology underlying our Helitope gastric cancer risk diagnostic.
The Problem with Peptide ELISAs
Anyone who's worked with peptide-based diagnostics knows the challenges. Unlike full proteins, peptides don't always play nicely with polystyrene surfaces. They're often highly soluble, struggle with passive adsorption, and frequently fail to present epitopes in the correct orientation for maximum antibody binding.
The standard workarounds require multiple steps and introduce their own problems. Maleimide coupling, biotin-avidin systems, carbodiimide crosslinking, or conjugation to carrier proteins like BSA all add cost, complexity, and processing time. Carrier proteins create significant non-specific background binding, and degrade signal-to-noise ratios. Chemical crosslinkers can bury epitopes or create steric hindrance that reduces binding affinity.
Our Solution: Direct Peptide Modification
Our approach directly modifies peptides during synthesis, eliminating traditional coupling agents entirely. No external conjugation chemistry is required.
The results speak for themselves:
Dramatically increased signal-to-noise ratio compared to conventional peptide ELISAs
Extremely low non-specific binding – critical for clinical diagnostics
Cost-effective manufacturing with modification performed during synthesis
Compatibility with common microplates and microsphere (bead) chemistries for multiplexed applications
Proven in Practice
This technology isn't theoretical – it's the foundation of our Helitope CagA ELISA that recently moved to manufactured test kits. Every peptide in those kits uses our approach, delivering the sensitivity and specificity required for clinical gastric cancer risk assessment.
The same technology that enables us to distinguish between less aggressive and oncogenic H. pylori strains can now accelerate diagnostic development across countless applications.
Multiple Commercialisation Pathways
We're exploring several avenues to bring this technology to market:
Custom Peptide Manufacturing We handle the manufacture and modification, and ship optimised peptides – including simple protocols for creating benchtop ELISA's for research
Full-Service Diagnostic Development We handle everything: from epitope discovery through to prototype validation, leveraging our complete peptide-ELISA platform
Technology Licensing Direct licensing to peptide manufacturers or ELISA kit developers to integrate our approach into their products
Each pathway addresses different market needs while maximising the technology's impact across the diagnostics industry.
Strategic IP Protection
Over the next 12 months we will be generating additional supporting data to strengthen our claims. We believe the approach will help solve multiple problems in biochemistry and biotech research beyond diagnostics.
Perfect Timing
We're announcing this patent filing as Biotome heads to BIO 2025 in Boston, where we'll be seeking partners across diagnostic development, vaccine optimisation, and strategic licensing.
For companies frustrated with traditional peptide-ELISA limitations, our technology offers a path to the sensitivity and reproducibility that clinical applications demand.
Looking Forward
We've solved the peptide-ELISA problem. It's time to get it in the hands of researchers.
We've removed the main technical barrier while keeping all the cost and flexibility advantages. This puts us in a strong position as precision medicine drives demand for better, cheaper diagnostics.
Ready to discuss how peptide augmentation can enhance your diagnostic development?
Find us at BIO 2025 in Boston (June 16-19) as part of the Australian delegation, or contact us directly to explore partnership opportunities.
Contact: Samuel Lundin, Founder & CEO (info@biotome.com.au)
Patent Reference: Australian Patent Application 2025902422
コメント